3 results
Investigate the activity and safety of amrubicin alone versus amrubicin incombination with cisplatin versus standard treatment for extensive disease(ED) small-cell lung cancer in the first line setting.
The primary objective is the Objective tumor response rate (RECIST). Secondary objectives are: duration of overall response, time to tumor progression (TTP), progression free survival (PFS), overall survival, toxicity profile, incidence of…
The primary objective of the study is to generate safety and performance data for the CardiAQ* Transcatheter Mitral Valve Implant System with the Transapical Delivery System to support a future marketing application for the treatment of moderate to…